Combining antiviral drugs with BET inhibitors is beneficial in combatting SARS‐CoV‐2 infection
Abstract The COVID‐19 pandemic caused by the novel coronavirus SARS‐CoV‐2 has resulted in more than 500 million cases and 6 million deaths. Several antiviral therapies and vaccines have been developed to mitigate the spread of this infection. However, new approaches are required to battle emerging S...
Saved in:
Main Authors: | Arpan Acharya (Author), Tatiana G. Kutateladze (Author), Siddappa N. Byrareddy (Author) |
---|---|
Format: | Book |
Published: |
Wiley,
2022-06-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Impact of Social Determinants of Health on the Emerging COVID-19 Pandemic in the United States
by: Sravani Singu, et al.
Published: (2020) -
SARS-CoV-2 cell entry and targeted antiviral development
by: Zinuo Chen, et al.
Published: (2021) -
Potential antiviral peptides targeting the SARS-CoV-2 spike protein
by: Ibrahim Khater, et al.
Published: (2022) -
Coronaviruses SARS-CoV, MERS-CoV, and SARS-CoV-2 helicase inhibitors: a systematic review of in vitro studies
by: Nimer Mehyar
Published: (2023) -
Jun12682, a potent SARS-CoV-2 papain-like protease inhibitor with exceptional antiviral efficacy in mice
by: Mianling Yang, et al.
Published: (2024)